Incannex Healthcare (IHL) partners with Sleep Research Centre at UWA to expand the IHL-42X OSA study program

2021-05-11 05:00:50 (AET) by Ring Zhang   689


Incannex Healthcare Limited (ASX: IHL), an ASX-Listed pharmaceutical development company, today announced its partnership agreement with the University of Western Australia Centre to expand the number of clinical sites for its ongoing dose-finding trial, which is investigating the effect of drug candidate IHL-42X in adults diagnosed with Obstructive Sleep Apnoea (‘OSA’).

Incannex Healthcare Limited (ASX: IHL) , an ASX-Listed pharmaceutical development company, today announced its partnership agreement with the University of Western Australia Centre to expand the number of clinical sites for its ongoing dose-finding trial, which is investigating the effect of drug candidate IHL-42X in adults diagnosed with Obstructive Sleep Apnoea (OSA).

The stock price of IHL was down by 3.17% compared to the close price yesterday.

text

The drug developer is currently conducting the phase 2b trial, which started late last year, at The Alfred Hospital in Melbourne with initial results pending. With the new partnership, the trial is now considered a multi-site study with extra medical and scientific professionals contributing to the program.

Patients diagnosed with OSA are treated with IHL-42X at 3 different dose levels in a randomised, double-blind and placebo-controlled cross over study to assess the therapeutic benefit of the drug. The primary endpoint in the trial is the reduction in Apnoea Hypopnea Index (‘AHI’), compared to baseline, or pre-treatment, levels. Participants are also monitored for improvements in alertness, daytime sleepiness, mood, and quality of life.

When commenting on the new partner, Incannex emphasised thatthe Centre for Sleep Science at the University of Western Australia is a world-class facility at the forefront of sleep research and sleep education, which ensures it works towards its vision of providing evidence-based education and conducting quality, clinically relevant research which will ultimately improve sleep health in the community.’

Director of the Centre for Sleep Science at the UWA, who also leads the sleep physiology research team at the West Australian Sleep Disorders Research Institute (‘WASDRI’) at Sir Charles Gairdner Hospital, will supervise the study.

Dr Jen Walsh said; “Given the number of people with OSA and the proportion unable to tolerate existing therapies, it is exciting to be working with Incannex on this trial of an alternate treatment option. Even patients who can tolerate existing therapies for their OSA would sometimes like the option to take a medication rather than sleep with a device.”

About Obstructive Sleep Apnoea (OSA)
Four in 10 Australian adults experience regular poor sleep, the consequences of which can have significant impacts on health, performance, and society. OSA is a highly prevalent condition affecting approximately 30M adults in the USA, yet treatment option is very limited. The main current treatment option for OSA is the mechanical CPAP device (Figure 1), users experience discomfort resulting from pressurised air being pumped into the patient’s nose and/or mouth during sleep.

text
Figure 1 mechanical CPAP device

OSA represents a major market opportunity of IHL and is one of six medicinal cannabinoid or psychedelic therapies under development at the company. IHL anticipates greatly improved patient treatment compliance and outcomes from a pharmaceutical product, which could be IHL-42X should it prove successful under clinical assessment.

【See more information about IHL, please click IHL


Source:
Incannex Healthcare Limited (ASX: IHL) 11.05.2021 ASX announcement: IHL-42X OSA Update


標簽:

聲明:這些資訊屬於事實信息,僅供參考,不應被視為投資建議或用於投資決策

版權所有,轉載需注明出處:61 澳洲財經資訊 news.61financial.com.au

商務合作請聯系 support@61financial.com.au


61 澳洲財經資訊郵件訂閱服務,每日為您推薦最新澳洲財經資訊


推廣

cover
訴訟對特斯拉股價的重壓

在最新發生的爭議中,如果特斯拉和SolarCity的審判結果不利於特斯拉CEO埃隆·馬斯克(Elon Musk),特斯拉可能被迫對股東進行賠償。這對特斯拉股價有何影響?

相關文章

cover
脫水簡報 - Incannex Healthcare個股分析

Incannex Healthcare(ASX: IHL)是一家臨床階段的藥物開發公司,為治療廣泛性焦慮症(GAD)、阻塞性睡眠呼吸暫停症(OSA)、創傷性腦損傷(TBI)/腦震蕩和急性呼吸窘迫綜合征(ARDS)開發獨特的藥用大麻藥物和迷幻藥物療法。

cover
金礦公司Regis季度黃金產量超11.4萬盎司,股價上揚近9%

黃金生產及勘探公司 Regis(ASX:RRL)在6月季度未發生任何環境違規或重大事件,作業安全情況得到持續改善。在該季度收購了Tropicana項目30%的股權後,公司6月季度的黃金產量超過11.4萬盎司,全年黃金產量將近37.3萬盎司,年度總維持成本(AISC)為1373澳元/盎司。

cover
脫水研報 - Fletcher Building與復合木材制造業

澳大利亞統計局本月公布的數據顯示,經季節性調整後,3月份季度的住宅開工單位總數上升了0.2%。新開工的私人住宅環比增加了5.9%,達到35,869個。建築工程總價值上升了3.0%,達到304億澳元。應 61 Financial VIP 用戶的要求,本周的研究報告分析了建築材料供應商 Fletcher Building (ASX: FBU)與澳大利亞復合木材制造業。

4 小時前